As pharmaceutical company executives continue to change, high-level talents become the focus of pharmaceutical companies' competition

Recently, Dizhe Pharmaceutical announced the appointment of Ms.
Wu Qingyi as Chief Commercial Officer
.
It is understood that Ms.
Wu has more than 25 years of industry experience in multinational pharmaceutical companies and biotech companies.
Previously, she served as the chief commercial officer of BeiGene Greater China, and business leadership positions such as Sanofi and AstraZeneca
.
This time, Ms.
Wu joined Dizhe Pharmaceutical as the chief commercial officer, and it is expected that it will play an important role in the commercialization of Dizhe Pharmaceutical
.
It is understood that Dizhe Pharmaceutical is an innovation-driven biomedical company, which has been established for less than 4 years and currently has no commercialization of any products
.
In addition to Dizhe Pharmaceuticals, according to incomplete statistics, there have been changes in the management of seven pharmaceutical companies since October
.
These include Northeast Pharmaceutical, Hengrui Pharmaceutical, Jiangsu Kangyuan Pharmaceutical, Beijing Kangchen Pharmaceutical, Jiangxi Fuxiang Pharmaceutical, Sansheng Guojian Pharmaceutical and Stellite
.
In this regard, the industry believes that in recent years, the core reasons for the continuous changes in the executives of the pharmaceutical industry are mainly due to several aspects: First, the environment of the pharmaceutical industry is constantly changing, and many executives have also changed their vision and thinking.
They have begun to look for new development opportunities; second, innovation has become an industry development trend.
With the decline in profits of most generic drugs, pharmaceutical companies have to face restructuring or even switching, which intensifies personnel changes; third, group companies The divestiture of non-performing assets is also accelerating the flow of related staff
.
In summary, the entire industry is facing the urgent need for transformation and upgrading with the rapid decline of Chinese generic drugs and the gradual rise of innovative drugs
.
This also means that in the next few years, China's pharmaceutical industry will continue to fluctuate, including changes in personnel, mergers and acquisitions, and so on
.
Among them, especially the turnover of core executives of pharmaceutical innovation companies will become more frequent, and the competition for high-level talents by pharmaceutical companies will also intensify
.
However, it should be noted that although the resignation of executives does have a certain wind direction effect, many people regard it as the "ruler" of career choice
.
But there are also many misleadings in this.
What is behind the executive's job-hopping involves personal development planning and the adjustment of the entire pharmaceutical company's strategy.

.
In fact, in recent years, the changes in the pharmaceutical industry are accelerating the pace of pharmaceutical marketing transformation and innovation, and the demand for relevant talents has also begun to change
.
Research has shown that in terms of pharmaceutical marketing talents, the demand for talents in foreign companies is shrinking, while the demand for talents in domestic companies is increasing; in addition, the talent gap of foreign companies is mainly in regional promotion managers, key account managers, regional managers, regional managers, etc.
The talent gap of domestic pharmaceutical companies is mainly in sales directors, regional directors, marketing directors, and post-market medical directors
.
In addition, as large-scale pharmaceutical companies are deploying in the field of tumor treatment and intensifying competition, domestic pharmaceutical companies are also gradually leaning toward talents related to innovative drugs, new medical treatments, and diagnosis in terms of talent acquisition
.
Therefore, judging from the above trends, the resignation of senior executives is more dependent on the needs of the company.
The different directions of transformation of pharmaceutical companies will lead to different needs for senior executives and talents
.
However, in general, medical professionals with strength and experience will always be high-level talents that pharmaceutical companies need
.
For the relevant staff, in the future, only by formulating a clear plan for their own careers, clarifying their choices and abilities, continuously improving their shortcomings, and having strong compliance capabilities, can they be in the background of frequent personnel changes in the pharmaceutical industry.
Have more competitiveness
.